ProblemSevere-asthma biologic patients still miss next doses after therapy starts because reauthorizations expire, specialty-pharmacy routing changes, and continuation proof is scattered across notes, labs, and payer letters; AMA says 95% of physicians see PA delays.
SolutionNextDose Asthma gives allergy and pulmonary clinics a renewal rescue board that flags expiring approvals, missing continuation evidence, wrong pharmacy routing, and benefit mismatches before staff rebuild the case by hand and patients slip off the injection calendar.
Market opportunityAsthma affects 28M+ Americans, AAAAI represents 7,000+ allergists, Dupixent alone has been prescribed to 165,000+ asthma patients, and adjacent clinic software already sells from $99 to $429+ per provider or month, leaving room for a narrow ops layer.